An update on the ENERGIZE-T trial of mitapivat in transfusion-dependent thalassemia

Описание: Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, provides an update on the ENERGIZE-T trial (NCT04770779), a Phase III open-label double-blind placebo-controlled study of mitapivat in patients with transfusion-dependent thalassemia (TDT). Prof. Cappellini notes that mitapivat significantly affects the metabolism of red cells in thalassemia, resulting in a meaningful reduction in transfusion dependence and ultimately in iron accumulation. The agent has also been shown to improve the quality of life (QoL) of patients, with individuals reporting improved well-being. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.